Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 52: 1785-1793, 2006. First published July 20, 2006; 10.1373/clinchem.2006.067546
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.067546v1
52/9/1785    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Hoeyveld, E.
Right arrow Articles by Bossuyt, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Hoeyveld, E.
Right arrow Articles by Bossuyt, X.
Related Collections
Right arrow Clinical Immunology
(Clinical Chemistry. 2006;52:1785-1793.)
© 2006 American Association for Clinical Chemistry, Inc.


Clinical Immunology

Quantification of IgG Antibodies to Aspergillus fumigatus and Pigeon Antigens by ImmunoCAP Technology: An Alternative to the Precipitation Technique?

Erna Van Hoeyveld1,a, Lieven Dupont2 and Xavier Bossuyt1

1 Department of Laboratory Medicine, Immunology, and 2 Department of Internal Medicine, Pneumology, University Hospital Leuven, Belgium.

aAddress correspondence to this author at: Department of Laboratory Medicine, Immunology, University Hospital Leuven, Herestraat 49, B-3000 Leuven, Belgium. Fax 00-32-13-347042; erna.vanhoeyveld{at}uz.kuleuven.ac.be.


   Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
Background: We evaluated the ImmunoCAP technique for measurement of IgG specific to Aspergillus fumigatus and pigeon antigens.

Methods: We used ImmunoCAP and precipitation technique to measure concentrations of IgG to A. fumigatus or pigeon antigens in sera from 265 patients and 42 controls. We also evaluated linearity, interference, imprecision, concordance, and diagnostic accuracy of the measuring techniques.

Results: The precipitation and ImmunoCAP technique showed moderate concordance ({kappa}, 0.46 for both A. fumigatus and pigeon antibodies). Specific IgG results for A. fumigatus and pigeon were linear (r = 0.98 and 0.97, respectively), with interrun reproducibility rates of 23% and 14% and maximal interference of 36.5% and 8% by lipid and 24% and 21% by hemolysis, respectively. A. fumigatus antibody concentrations were higher in patients with aspergillosis and allergic bronchopulmonary aspergillosis (ABPA) (median, 103 and 70.1 mgA/L, respectively) than in patients with other pulmonary diseases (median, 18.15–33.40 mgA/L). Antibodies to pigeon antigens were high in patients with hypersensitivity pneumonitis (median, 1024 mgA/L) but also in patients with other pulmonary diseases (median, 445 mgA/L). Antibody titers were substantially higher in patients with other pulmonary diseases and contact with pigeons (median, 1060 mgA/L) than in patients without antigen contact (median, 27.35 mgA/L) (P <0.004).

Conclusions: Agreement between the precipitation and ImmunoCAP technique was 86% for A. fumigatus and 70% for pigeon antigens. Highest concentrations of specific IgG to A. fumigatus were found in patients with aspergillosis and ABPA. Our results suggest that antigen contact was the most important variable affecting the presence of antibodies to pigeon antigen.


   Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
Organic dust is known to be involved in the pathogenesis of hypersensitivity pneumonitis. Diagnosis is based on characteristic clinical symptoms and demonstration of antigen-specific IgGs(1)(2)(3)(4). Antigen exposure also elicits production of IgGs in other pulmonary diseases, such as invasive aspergillosis(5)(6), allergic bronchopulmonary aspergillosis (ABPA)1 (7), and ABPA in cystic fibrosis(8).

A widely used method to detect specific IgG in clinical laboratories is the immunoprecipitation technique. However, detection of precipitating antibodies has disadvantages. Specificity(9) and sensitivity(10)(11) are limited, reproducibility is poor, and antibody concentrations cannot be measured(11). Moreover, this method is time-consuming and therefore not recommended for routine purposes(11)(12).

Other immunodiffusion assays, such as counterimmunoelectrophoresis(5) and radioimmunoprecipitation(13)(14), are more rapid tests with lower detection limits than the precipitation technique. Although ELISA was shown to be even more sensitive and reliable than immunodiffusion(9)(10)(15), its suboptimal specificity can lead to false-positive results, identifying clinically irrelevant IgG responses.

Recently, an automated technique for detecting specific IgG has become available on the ImmunoCAP system (Sweden Diagnostics). Agreement between specific IgG determination on ImmunoCAP and the precipitation technique has been reported in a limited number of selected patients(12)(16), but data on the performance of ImmunoCAP in a routine clinical setting are lacking.

In this study, we evaluated the diagnostic performance of ImmunoCAP for detecting antigen-specific antibodies. The distributions of IgG specific to A. fumigatus and pigeon antigens was determined in a healthy nonexposed control population and in different groups of patients with well-defined pulmonary diseases. The results were compared with results obtained with the precipitation technique.


   Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
study population
We collected sera from 42 healthy female laboratory technicians, ages 25–61 years, who had no history of allergy to A. fumigatus or avian antigens and no contact with birds. Over a 1-year period, (January 2004 to January 2005), we also collected sera from 223 consecutive patients from the Departments of Internal Medicine and Paediatrics to ensure a random sampling. For these serum samples, we determined serum precipitins against A. fumigatus and/or pigeon serum antigens. Also included in the study were 42 stored patient sera, collected over a 2-year period (January 2003 to December 2004), with a high number of precipitation lines (≥4) for one or both antigens. Samples from 56 patients were excluded because medical data on the patients were not available. For all patients included in the study, there were no indeterminate or missing results. We tested 219 patient sera for A. fumigatus antibodies [98 males (ages 2–91 years; median, 24 years) and 92 females (ages 4–83 years; median, 24.5 years)], and 46 sera for pigeon antibodies [9 females and 37 males (ages 21–81 years; median, 66 years)]. Performing the study had no adverse effects on the participants.

precipitation technique
Extracts.
A. fumigatus strain BC 192.65 was obtained from the Centraal Bureau voor Schimmelculturen (Baarn, the Netherlands) and grown on Sabouraud agar (Sanofi Diagnostics Pasteur) for 5 days. Afterward, the fungus was grown by shaking in 250 mL of Czapek-Dox broth with an initial pH 5.0 in 1-L flasks at 37 °C for 3–4 weeks(17). The culture filtrate was separated from mycelia by passage through Whatman no. 4 paper. Filtrates from different flasks were pooled and dialyzed against distilled water at 4 °C (relative molecular mass cutoff, 10 000). The medium was freeze-dried and reconstituted at a concentration of 250 g/L in distilled water.

Lyophilized pigeon serum was obtained from Hal Laboratories. Before use, it was dissolved in 1 mL of distilled water at a concentration of 30 g/L.

Procedure.
The test was performed by standard Ouchterlony technique(18) in 1.5% agarose. Undiluted patient serum (275 µL) was placed in the central well and antigens (35 µL) were placed in the peripheral wells. Plates were incubated for 5 days at room temperature, rinsed with 5% trisodium citrate to remove aspecific S-polysaccharide-C-reactive protein lines, washed with 0.9% NaCl, dried, and stained with Amido Black. Results were expressed as number of precipitation lines. The assay was performed by 2 experienced technologists who were blinded for the results of the reference standard.

immunocap technology
Specific IgG was determined on the same frozen samples as the precipitating antibodies. Quantification was done in one center with one UniCAP 100 system (Sweden Diagnostics), according to the manufacturer’s instructions. Results were expressed as milligrams of antigen-specific antibodies (mgA) per liter. Concentrations for 1/100 diluted samples were 2–200 mgA/L. Samples with concentrations >200 mgA/L were further diluted and retested. Sera were investigated for the presence of A. fumigatus (gm3) and/or pigeon (ge91) IgG. The assay was performed by 2 experienced technologists who were blinded for the results of the reference standard.

evaluation details
Specific IgG was determined on frozen material after collection of all samples. Within-assay and between-assay variability were calculated according to CLSI (formerly NCCLS) guidelines(19). For both A. fumigatus and pigeon, 1 sample was assayed 20 times within the same run, and 2 samples were assayed in 20 different runs.

To investigate interference by lipids, samples were supplemented with different dilutions of a serum with high triglyceride concentration (9.09 g/L) as described previously(20). The effect of hemoglobin was studied by adding increasing concentrations (up to 4.6%) of human hemolysate, as described previously(20).

The reference standard was the clinical diagnosis. Data on diagnosis and exposure were collected retrospectively from the medical records. All medical records were reviewed by an experienced pneumologist. Diagnoses were based on criteria described by Denning(21) for aspergillosis, by Greenberger et al.(22) for ABPA, by the 2004 NIH report(23) for bronchial asthma, by Rosenstein et al.(24) for cystic fibrosis, and by Stevens et al.(25) for ABPA in cystic fibrosis (cystic fibrosis and ABPA). Another group consisted of patients with bronchiectases that were not the result of CF or ABPA. Other pulmonary diseases for which A. fumigatus antibodies were ordered by the physician were classified as "other pulmonary diseases". Diagnosis of pigeon breeder’s disease was based on criteria of Richerson et al.(26)

statistical analysis
The distribution of IgG concentrations was described by continuous summary descriptives (Analyze-it, version 1.62; Smart Software).

Differences in median concentrations of specific IgG were tested by the Mann–Whitney U-test. For differences in the number of precipitation lines, the {chi}2 test was used; P <0.05 was considered significant.

ROC plot analyses were performed with Analyze-it.


   Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
linearity
Dilution of a sample with a high concentration of IgG to A. fumigatus (161 mgA/L) with sample diluent (0%–100% with increments of 10%) was linear (r = 0.98), as was dilution of a sample with a high concentration of IgG to pigeon (178 mgA/L) (r = 0.97).

imprecision
Within-run CV (n = 20) was 3% for A. fumigatus IgG (concentration, 56.5 mgA/L) and 10% for antipigeon IgG (concentration, 386 mgA/L). Between-run CVs (n = 20) for A. fumigatus IgG were 23% for an antibody concentration of 42.7 mgA/L and 15% for an antibody concentration of 146 mgA/L. Between-run CVs for antipigeon IgG were 14% for an antibody concentration of 484 mgA/L and 10% for an antibody concentration of 1612 mgA/L.

interferences
To evaluate interference by hemoglobin and triglycerides, increasing amounts of these substances were added to a sample containing 20.2 and 24.1 mgA/L A. fumigatus IgG, respectively. The specific antibody concentrations were 20.3, 17.7, 18, 17.2, and 15.3 mgA/L for final hemoglobin concentrations of 2.88, 5.75, 11.5, 23, and 46 g/L, respectively, and 25.2, 23.1, 27.8, 27.2, 32.1, and 32.9 mgA/L for final triglyceride concentrations of 0.454, 0.908, 1.816, 2.72, 3.63, and 4.54 g/L, respectively.

The same amounts of hemoglobin and triglycerides were added to a sample containing, respectively, 7.32 and 92.1 mgA/L pigeon IgG. The IgG concentrations were 6.74, 6.37, 6.64, 6.89, and 6.03 mgA/L for final hemoglobin concentrations of 2.88, 5.75, 11.5, 23, and 46 g/L, respectively, and 87.2, 90.1, 92.1, 90.4, 94.5, and 99.3 mgA/L for final triglyceride concentrations of 0.454, 0.908, 1.816, 2.72, 3.63, and 4.54 g/L, respectively.

control group
Low concentrations of IgG to A. fumigatus and pigeon antigens were detected in sera of healthy controls. The median values were 13.75 mgA/L for A. fumigatus and 6.64 mgA/L for pigeon antigen; the 97.5th percentile values were 70.1 and 19.5 mgA/L, respectively (Table 1 ).


View this table:
[in this window]
[in a new window]
 
Table 1. Distribution and number of patients above and below cutoff values for specific IgG antibody concentrations to Aspergillus fumigatus in healthy controls, in diseased controls (patients with AB,1 CF, CF + ABPA, BRECT, and OPDs), and in patients with ASP and ABPA; distribution of specific IgG antibody concentrations to pigeon antigens in healthy controls, in diseased controls (non-PBD) and in PBD

correlation between specifc IGG determination and the precipitation technique
The correlation between specific IgG concentrations and the number of precipitation lines is shown in Fig. 1 . Agreement between tests was 86% for A. fumigatus and 70% for pigeon antibodies ({kappa}, 0.46, for both A. fumigatus and pigeon).


Figure 1
View larger version (14K):
[in this window]
[in a new window]
 
Figure 1. Correlation between specific IgG concentrations and the number of precipitation lines.

(Upper panel), Relation of the number of precipitation lines and specific IgG antibody concentrations for Aspergillus fumigatus in patients with aspergillosis (ASP), allergic bronchopulmonary aspergillosis (ABPA), bronchial asthma (AB), cystic fibrosis (CF), bronchiectasis (BRECT), and other pulmonary diseases (OPD). (Lower panel), Relation of the number of precipitation lines and specific IgG antibody concentrations for pigeon antigens in patients with pigeon breeder’s disease (PBD) and without pigeon breeder’s disease (non-PBD).

IGG antibody values among different patient groups
The median concentrations of IgG to A fumigatus and pigeon in healthy controls and in different patient groups are given in Table 1Up .

IgG to A. fumigatus was determined in 219 patients with the following diagnoses: aspergillosis (n = 10, comprising 9 patients with invasive aspergillosis and 1 with aspergilloma), ABPA (n = 10), bronchial asthma (n = 20), cystic fibrosis (n = 112), cystic fibrosis and ABPA (n = 11), bronchiectases not caused by cystic fibrosis or to ABPA (n = 8), and miscellaneous pulmonary diseases, including chronic obstructive pulmonary disease (COPD) and pneumonia (n = 48).

High concentrations of IgG to A. fumigatus were found in patients with aspergillosis (median, 103 mgA/L; 25th–75th percentiles, 90.95–147 mgA/L) and in patients with ABPA (median, 70.1 mgA/L; 25th–75th percentiles, 41.83–113.45 mgA/L) (Table 1Up ). Differences were highly significant compared with healthy controls (P <0.0001). In other pulmonary diseases, median values were 18.15–33.40 mgA/L (Table 1Up ). Except in patients with bronchial asthma, IgG concentrations were significantly higher than in controls but substantially lower than in patients with aspergillosis and ABPA (P ≤ 0.001 for aspergillosis and P ≤ 0.02 for ABPA). IgG concentrations in patients with aspergillosis were not substantially different from those in patients with ABPA (P = 0.19).

We measured IgG to pigeon antigens in samples from 46 patients, including patients with pigeon breeder’s disease (n = 20), COPD (n = 15), bronchial asthma (n = 1), idiopathic lung fibrosis (n = 5), pneumonia (n = 1), infection (n = 2), and other diseases (n = 2). IgG was extremely high in patients with pigeon breeder’s disease (median, 1024 mgA/L; 25th–75th percentiles, 484-1720). High concentrations of pigeon antibodies were also found in patients without pigeon breeder’s disease (median, 445 mgA/L; 25th–75th percentiles, 25.75–1150) (Table 1Up ). Differences were highly significant compared with healthy controls (P <0.0001 for pigeon breeder’s disease patients and P <0.001 for patients without pigeon breeder’s disease). Patients with pigeon breeder’s disease tended to have higher antipigeon IgG values than patients without pigeon breeder’s disease (P = 0.07).

distribution of IGG antibody concentrations and diagnostic performance
The logarithmic distribution of A. fumigatus IgG in healthy controls, in patients with aspergillosis and ABPA, and in diseased controls (bronchial asthma, cystic fibrosis, cystic fibrosis and ABPA, bronchiectases, and other pulmonary diseases) is illustrated in Fig. 2 . Because IgG values in patients with aspergillosis and ABPA were comparable (Table 1Up ) and because these are the medical conditions typically associated with the presence of antigen-specific antibodies, these 2 groups were taken together. All other patient groups were considered as diseased controls. There was a minor overlap between healthy controls and patients (aspergillosis and ABPA), but the majority of the patients had substantially higher antibody concentrations than the controls. Values obtained in diseased controls overlapped those for healthy controls and patients, with the greatest overlap with healthy controls. ROC curve analysis revealed areas under the curve of 0.957 and 0.859 for differentiating aspergillosis and ABPA patients from healthy individuals and diseased controls, respectively. The cutoff points with the highest sum of detection limit and specificity were 35.9 and 35.2 mgA/L, respectively, when healthy controls or diseased controls were taken as reference. At these cutoff points, the detection limit for detecting aspergillosis and ABPA was 90% (95% CI, 68.3%–98.8%). The specificities were 85.7% (95% CI, 71.5%–94.6%) and 65.3% (95% CI, 58.3%–71.9%), respectively, when healthy or diseased controls were considered. Recalculation of these data at a cutoff point of 70 mgA/L, corresponding to the 97.5th percentile of our healthy controls, produced a sensitivity of 70% (95% CI, 45.7%–88.1%) and a specificity of 97.6% (95% CI, 87.4%–99.9%). When diseased controls were considered as a control group, the specificity decreased to 85.9% (95% CI, 80.3%–90.4%). The number of patients with values above and below these cutoff points of 35 and 70 mgA/L are given in Table 1Up .


Figure 2
View larger version (36K):
[in this window]
[in a new window]
 
Figure 2. Distribution of IgG antibody values (log mgA/L) to Aspergillus fumigatus in a healthy control group (white bars), in diseased controls (patients with bronchial asthma, cystic fibrosis, cystic fibrosis and ABPA, bronchiectasis, and other pulmonary diseases) (gray bars), and in patients with aspergillosis and ABPA (black bars).

The distribution of IgG to pigeon antigens in healthy controls and in patients with or without (diseased controls) pigeon breeder’s disease is shown in Fig. 3 . Controls had clearly lower pigeon antibodies than diseased people. All control individuals had IgG values <20 mgA/L to pigeon, whereas >89% of the diseased individuals had values >20 mgA/L. However, it was impossible to distinguish patients with and without pigeon breeder’s disease on the basis of pigeon IgG concentrations (Fig. 3 ). This finding was confirmed by ROC curve analysis. The area under the curve was only 0.614.


Figure 3
View larger version (26K):
[in this window]
[in a new window]
 
Figure 3. Distribution of IgG antibody values (log mgA/L) to pigeon antigens in a healthy control group (white bars) and in patients with (gray bars) and without (black bars) pigeon breeder’s disease.

influence of antigen contact on antibody production
To further explore the diagnostic utility of antipigeon IgG determination, we subdivided patients with and without pigeon breeder’s disease on the basis of presence or absence of antigen contact.

The number of precipitation lines to pigeon serum antigens was clearly different between pigeon breeder’s disease patients with and without current exposure (Fig. 4A ). Four of the 5 pigeon breeder’s disease patients without active contact with pigeons had 1 or 0 precipitating lines. In pigeon breeder’s disease patients with actual exposure, >80% had ≥4 precipitation lines. Fig. 4B shows the IgG concentrations to pigeon antigens in the same patient groups. The differentiation between IgG concentrations in pigeon breeder’s disease patients with or without actual antigen contact was highly significant (P <0.002). All diseased patients without contact with pigeons had antibody concentrations <500 mgA/L, whereas patients with contact had concentrations ≥500 mgA/L, except for 1 patient receiving steroid therapy.


Figure 4
View larger version (13K):
[in this window]
[in a new window]
 
Figure 4. Influence of antigen contact on the number of precipitation lines (A and C) and on the concentration of specific IgG antibodies (B and D) in patients with pigeon breeder’s disease (PBD) and without pigeon breeder’s disease (non-PBD).

The number of precipitation lines and IgG concentrations in sera from patients without pigeon breeder’s disease are shown in Fig. 4Up , C and D. The patient subgroup with antigen contact had a higher number of precipitation lines (P <0.02), a finding that was even more pronounced when IgG concentrations were measured by ImmunoCAP. The antibody concentration in patients without pigeon breeder’s disease without antigen contact (median, 27.35 mgA/L; n = 10) was significantly lower (P <0.004) than in patients with antigen contact (median, 1060 mgA/L; n = 13). Of the patients without pigeon breeder’s disease and without antigen contact (n = 10), 4 were former pigeon breeders. IgG concentrations in these patients were higher than in healthy controls. The antibody concentration in the other nonexposed patients without pigeon breeder’s disease was, except for 1 patient, comparable to the concentration in nondiseased controls. Finally, we compared the number of precipitation lines and the concentration of IgG to pigeon between exposed pigeon breeder’s disease patients and exposed patients with other pulmonary diseases. IgG titers to pigeon antigens in exposed pigeon breeder’s disease patients (median, 1280 mgA/L; n = 11) were comparable to the titers found in exposed patients with other pulmonary diseases (median, 1060 mgA/L; n = 13) (P = 0.41). Similarly, a comparable number of precipitation lines was found in both groups of patients (data not shown).


   Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
We evaluated the ImmunoCAP technique for measuring IgG antibodies to A. fumigatus and pigeon antigens. Evaluation was done by comparison with the well-established precipitation technique and with clinical diagnosis. The ImmunoCAP test demonstrated acceptable technical performance.

Samples with a high number of precipitation lines had high IgG antibody concentrations with ImmunoCAP, and vice versa. However, a few samples without precipitating antibodies had rather high IgG values, and some samples with precipitating antibodies had low IgG values. Similar observations have been reported(11)(12)(27)(28)(29) and may be partly explained by differences in assay detection limit and quality and composition of the antigen extract. Indeed, pigeon serum antigen was used in the precipitation assay, whereas the antigen coupled to the ImmunoCAP contained proteins from serum, feathers, and droppings.

Precipitating antibodies to A. fumigatus were reported as highly reliable in patients with aspergillosis(9). Specific IgG is considered a major criterion for diagnosis of ABPA(8)(30). We confirmed that aspergillosis and ABPA patients had high numbers of precipitating antibodies and high concentrations of anti-A. fumigatus IgG.

Previous reports also described colonization with A. fumigatus in patients with cystic fibrosis(13)(31)(32), COPD, and pulmonary infection(33)(34)(35). All patient groups, except those with bronchial asthma, had substantially higher concentrations of specific IgG to A. fumigatus than did nondiseased controls but significantly lower concentrations than the aspergillosis and ABPA patient groups (Table 1Up ). At a cutoff point of 70 mgA/L, corresponding to the 97.5th percentile of the values obtained in 42 healthy, nonexposed controls, detection limit was 70% and specificity was 97.6% with healthy controls as a control group and 85.9% when diseased controls were considered. Hashemi(16) proposed a cutoff value of 126 mgA/L. The difference in cutoff values might be related to differences in exposure to A. fumigatus, a ubiquitous antigen, as also suggested by Makkonen et al.(36), who found moderate IgG titers in healthy controls that indicated exposure to mold-derived antigens.

Precipitating antibodies and IgG to pigeon antigens were found in patients with pigeon breeder’s disease. However, these antibodies were also found in many diseased patients without pigeon breeder’s disease who had been exposed to pigeon antigen. Other investigators also found antibodies in sera of asymptomatic but exposed individuals(10). Contact with antigen led to the production of high concentrations of anti-pigeon serum antibodies, meaning that no differentiation was possible between exposed individuals without pigeon breeder’s disease and individuals with pigeon breeder’s disease.

We collected data on exposure for every patient and found that contact with antigen was the most important variable related to antibody production. Patients with antigen contact had specific IgG values >500 mgA/L. Nonexposed control individuals had values <20 mgA/L. In comparison, Lopata et al.(12) reported a cutoff of 9.8 mg/L. Most patients without pigeon breeder’s disease with values of 20–500 mgA/L, including patients with dyspnea and COPD, had a history of contact with pigeons.

By the use of clinically well-defined patient groups in combination with data on antigen exposure, our study demonstrated agreement between the precipitation technique and the automated ImmunoCAP technique for the detection of antibodies to A. fumigatus and pigeon antigens. High concentrations of specific antibodies to A. fumigatus were found in patients with aspergillosis and ABPA. The presence of IgG antibodies to pigeon antigens indicates exposure to pigeons in individuals with or without pigeon breeder’s disease.


   Acknowledgments
 
We are grateful to Sweden Diagnostics, Brussels, Belgium for providing the reagents for this study. We are also grateful to Jacqueline L’Heureux and Lieve Godefridis for expert technical assistance.


   Footnotes
 
1 Nonstandard abbreviations: ABPA, allergic bronchopulmonary aspergillosis; COPD, chronic obstructive pulmonary disease; CI, confidence interval.


   References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 

  1. Rodriguez de Castro F, Carrillo T, Castillo R, Blanco C, Diaz F, Cuevas M. Relationships between characteristics of exposure to pigeon antigens. Clinical manifestations and humoral immune response. Chest 1993;103:1059-1063.[Abstract/Free Full Text]
  2. Fink JN. Hypersensitivity pneumonitis. J Allergy Clin Immunol 1973;52:309-317.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  3. Pelikan Z, Schlot JDL, Koedijk FHJ. The late bronchus-obstructive response to bronchial challenge with pigeon faeces and its correlation with precipitating antibodies (IgG) in the serum of patients having long-term contact with pigeons. Clin Allergy 1983;13:203-211.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  4. Grech V, Vella C, Lenicker H. Pigeon breeder’s lung in childhood: varied clinical picture at presentation. Pediatr Pulmonol 2000;30:145-148.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  5. Holmberg K, Berdischewsky M, Young LS. Serologic immunodiagnosis of invasive aspergillosis. J Infect Dis 1980;141:656-663.[Web of Science][Medline] [Order article via Infotrieve]
  6. Miller WT. Aspergillosis: A disease with many faces. Semin Roentgenol 1996;31:52-66.[Web of Science][Medline] [Order article via Infotrieve]
  7. Krasnick J, Greenberger PA, Roberts M, Patterson R. Allergic bronchopulmonary aspergillosis: serologic update for 1995. J Clin Lab Immunol 1995;46:137-142.[Medline] [Order article via Infotrieve]
  8. Skov M, Koch C, Reimert CM, Poulsen LK. Diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis. Allergy 2000;55:50-58.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  9. Schonheyder H, Andersen P. IgG antibodies to purified Aspergillus fumigatus antigens determined by enzyme-linked immunosorbent assay. Int Arch Allergy Appl Immunol 1984;74:262-269.[Web of Science][Medline] [Order article via Infotrieve]
  10. Rodrigo MJ, Benavent MI, Cruz MJ, Rosell M, Murio C, Pascual C, et al. Detection of specific antibodies to pigean serum and bloom antigens by enzyme linked immunosorbent assay in pigean breeder’s disease. Occup Environ Med 2000;57:159-164.[Abstract/Free Full Text]
  11. Aberer W, Woltsche M, Woltsche-Kahr I, Kranke B. IgG antibodies typical for extrinsic allergic alveolitis-An interlaboratory quality assessment. Eur J Med Res 2001;6:498-504.[Web of Science][Medline] [Order article via Infotrieve]
  12. Lopata AL, Schinkel M, Potter PC, Jeebhay MF, Hashemi C, Johansson SG, et al. Qualitative and quantitative evaluation of bird-specific IgG antibodies. Int Arch Allergy Immunol 2004;134:173-178.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  13. el-Dahr JM, Fink R, Selden R, Arruda LK, Platts-Mills TA, Heymann PW. Development of immune responses to Aspergillus at an early age in children with cystic fibrosis. Am J Respir Crit Care Med 1994;150:1513-1518.[Abstract]
  14. Patterson R, Greenberger PA, Ricketti A, Roberts M. A radioimmunoassay index for allergic bronchopulmonary aspergillosis. Ann Intern Med 1983;99:18-22.[Abstract/Free Full Text]
  15. Simpson C, Shirodaria PV, Evans JP, Simpson DIH, Stanford CF. Comparison of immunodiffusion and enzyme linked immunosorbent assay in the detection of abnormal antibodies in pigeon breeder’s disease. J Clin Pathol 1992;45:490-493.[Abstract/Free Full Text]
  16. Hashemi C. Quantification of IgG antibodies to mold antigens in the diagnosis of allergic alveolitis. New Horiz 2003;2:1-5.[Medline] [Order article via Infotrieve]
  17. Longbottom JL. Immunological investigation of Aspergillus fumigatus in relation to disease in man [PhD Dissertation] 1964 University of London London, United Kingdom. .
  18. Obexer G, Ebner H, Feldner H, Rumpold H, Kraft D. Extrinsic allergic alveolitis: comparison of 2 methods (Ouchterlony gel precipitation and ELISA) for antibody detection in routine diagnosis. Wien Klin Wochenschr 1983;95:789-791.[Web of Science][Medline] [Order article via Infotrieve]
  19. . National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices, 2nd ed.; tentative guideline. NCCLS Document EP5–T2 1992:12 (4). NCCLS Villanova, PA. .
  20. Bossuyt X, Schiettekatte G, Bogaerts A, Blanckaert N. Serum protein electrophoresis by CZE 2000 clinical capillary electrophoresis system. Clin Chem 1998;44:749-759.[Abstract/Free Full Text]
  21. Denning DW. Diagnosis and management of invasive aspergillosis. Curr Clin Top Infect Dis 1996;16:277-299.[Medline] [Order article via Infotrieve]
  22. Greenberger PA, Patterson R. Diagnosis and management of allergic bronchopulmonary aspergillosis. Ann Allergy 1986;56:444-448.[Web of Science][Medline] [Order article via Infotrieve]
  23. National Heart, Lung, and Blood Institute, NIH. Asthma management and prevention. Global Initiative for Asthma. A practical guide for public health officials and healthcare professionals: based on the global strategy for asthma management and prevention. NHLBI/WHO Workshop Report 1995. NIH publication no. 96-3659 (updated report October 2004)..
  24. Rosenstein BJ. What is a cystic fibrosis diagnosis?. Clin Chest Med 1998;19:423-441.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  25. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, et al. Participants in the Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003;37(Suppl 3):225-264.[CrossRef]
  26. Richerson HB, Bernstein IL, Fink JN, Hunninghake GW, Novey HS, Reed CE, et al. Guidelines for the clinical evaluation of hypersensitivity pneumonitis. Report of the subcommittee on hypersensitivity pneumonitis. J Allergy Clin Immunol 1989;84:839-844.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  27. Baldwin CI, Stevens B, Connors S, Todd A, Bourke SJ, Calvert JE, et al. Pigeon fanciers’ lung: the mucin antigen is present in droppings and pigeon bloom. Int Arch Allergy Immunol 1998;117:187-193.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  28. Hisauchi-Kojima K, Sumi Y, Miyashita Y, Miyake S, Toyoda H, Kurup VP, et al. Purification of the antigenic components of pigeon dropping extract, the responsible agent for cellular immunity in pigeon breeder’s disease. J Allergy Clin Immunol 1999;106:1158-1165.
  29. McSharry C, Anderson K, Boyd G. A review of antigen diversity causing lung disease among pigeon breeders. Clin Exp Allergy 2000;30:1221-1229.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  30. Elliott MW, Taylor AJN. Allergic bronchopulmonary aspergillosis. Clin Exp Allergy 1997;27(Suppl 1):55-59.
  31. Knutsen AP, Mueller KR, Hutcheson PS, Slavin RG. Serum antiAspergillus fumigatus antibodies by immunoblot and ELISA in cystic fibrosis with allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1994;93:926-931.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  32. Feanny S, Forsyth S, Corey M, Levison H, Zimmerman B. Allergic bronchopulmonary aspergillosis in cystic fibrosis: a secretory immune response to a colonizing organism. Ann Allergy 1988;60:64-68.[Web of Science][Medline] [Order article via Infotrieve]
  33. Thommi G, Bell G, Liu J, Nugent K. Spectrum of invasive pulmonary aspergillosis in immunocompetent patients with chronic obstructive pulmonary disease. South Med J 1991;84:828-831.[Web of Science][Medline] [Order article via Infotrieve]
  34. Treger TR, Visscher DW, Bartlett MS, Smith JW. Diagnosis of pulmonary infection caused by Aspergillus: usefulness of respiratory cultures. J Infect Dis 1985;152:572-576.[Web of Science][Medline] [Order article via Infotrieve]
  35. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, Leon C, Alvarez-Lerma F, Nolla-Salas J, et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005;9:R191-R199.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  36. Makkonen K, Viitala KI, Parkkila S, Niemela O. Serum IgG and IgE antibodies against mold-derived antigens in patients with symptoms of hypersensitivity. Clin Chim Acta 2001;305:89-98.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.067546v1
52/9/1785    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Hoeyveld, E.
Right arrow Articles by Bossuyt, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Hoeyveld, E.
Right arrow Articles by Bossuyt, X.
Related Collections
Right arrow Clinical Immunology


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS